Wave Life Sciences Ltd
$ 5.73
-5.91%
05 Jun - close price
- Market Cap 1,102,465,000 USD
- Current Price $ 5.73
- High / Low $ 6.12 / 5.61
- Stock P/E N/A
- Book Value 2.76
- EPS -1.05
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.53 %
- 52 Week High 21.73
- 52 Week Low 5.02
About
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development platform. The company is headquartered in Singapore.
Analyst Target Price
$21.94
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-26 | 2025-11-10 | 2025-07-30 | 2025-05-08 | 2025-03-04 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.1303 | -0.3 | -0.32 | -0.31 | -0.29 | 0.17 | -0.466 | -0.25 | -0.24 | -0.15 | 0.07 | -0.2 |
| Estimated EPS | -0.3213 | -0.2704 | -0.2547 | -0.27 | -0.2556 | -0.17 | -0.28 | -0.21 | -0.21 | -0.23 | -0.18 | -0.33 |
| Surprise | 0.191 | -0.0296 | -0.0653 | -0.04 | -0.0344 | 0.34 | -0.186 | -0.04 | -0.03 | 0.08 | 0.25 | 0.13 |
| Surprise Percentage | 59.446% | -10.9467% | -25.638% | -14.8148% | -13.4585% | 200% | -66.4286% | -19.0476% | -14.2857% | 34.7826% | 138.8889% | 39.3939% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WVE
2026-06-01 12:10:06
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, will participate in two investor conferences in June 2026. He will present at the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th, both featuring analyst-led fireside chats. Live webcasts and limited-time replays of these presentations will be available on the company's investor relations website.
2026-05-31 10:10:08
Wave Life Sciences' investigational RNA editor WVE-006 shows promising RestorAATion-2 data, effectively reducing harmful Z-AAT protein and restoring protective M-AAT to MZ-like levels with a favorable safety profile. This development strengthens the specific investment case for Wave's AATD program, especially after regaining full rights to WVE-006 from GSK. However, investors still need to consider the company's widening net losses and dependence on future milestones.
2026-05-30 06:09:38
Wave Life Sciences (WVE) has seen its internal fair value estimate decrease to $22.19, reflecting updated analyst assumptions due to obesity data and GLP-1 competition. Despite this, positive early clinical data for its obesity candidate WVE-007, showing significant fat reduction and lean mass gain, and ongoing RNA platform validation are highlighted as potential growth drivers. The company plans to advance WVE-007 into Phase 2a and other trials in 2026, while also navigating regulatory changes and relying on strategic partnerships for financial stability.
2026-05-28 23:28:00
This article from Stock Traders Daily analyzes Wave Life Sciences Ltd. (NYSE: WVE), identifying positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It outlines institutional trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis, all generated by AI models. The report also highlights a lack of clear price positioning signals and elevated downside risk.
2026-05-28 07:39:09
Wedbush has reiterated its Buy rating for Wave Life Sciences (WVE.US) and maintained its target price at $15. This suggests continued confidence in the company's performance and future prospects from the analyst firm.
2026-05-27 12:39:49
Johnson Fistel, PLLP is investigating Wave Life Sciences Ltd. (NASDAQ: WVE) for potential federal securities law violations following a significant stock decline. The investigation stems from the company's announcement of interim Phase 1 data for WVE-007, an investigational treatment for overweight or obesity, which, despite showing some positive results, led to a sharp drop in Wave's stock price. Shareholders who experienced losses are encouraged to contact Johnson Fistel to explore potential recovery under federal securities laws.
